RU2019102202A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019102202A3 RU2019102202A3 RU2019102202A RU2019102202A RU2019102202A3 RU 2019102202 A3 RU2019102202 A3 RU 2019102202A3 RU 2019102202 A RU2019102202 A RU 2019102202A RU 2019102202 A RU2019102202 A RU 2019102202A RU 2019102202 A3 RU2019102202 A3 RU 2019102202A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356410P | 2016-06-29 | 2016-06-29 | |
| US62/356,410 | 2016-06-29 | ||
| PCT/US2017/040106 WO2018005867A2 (en) | 2016-06-29 | 2017-06-29 | Structure-based peptide inhibitors of alpha-synuclein aggregation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022103498A Division RU2022103498A (ru) | 2016-06-29 | 2017-06-29 | Структурные пептидные ингибиторы агрегации альфа-синуклеина |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019102202A RU2019102202A (ru) | 2020-07-29 |
| RU2019102202A3 true RU2019102202A3 (ru) | 2020-10-30 |
| RU2766711C2 RU2766711C2 (ru) | 2022-03-15 |
Family
ID=60786477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019102202A RU2766711C2 (ru) | 2016-06-29 | 2017-06-29 | СТРУКТУРНЫЕ ПЕПТИДНЫЕ ИНГИБИТОРЫ АГРЕГАЦИИ α-СИНУКЛЕИНА |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10815271B2 (ru) |
| EP (1) | EP3478311A4 (ru) |
| JP (3) | JP6968839B2 (ru) |
| KR (2) | KR102554448B1 (ru) |
| CN (2) | CN116650617A (ru) |
| CA (1) | CA3029676A1 (ru) |
| IL (1) | IL263913B1 (ru) |
| MX (2) | MX2019000047A (ru) |
| RU (1) | RU2766711C2 (ru) |
| WO (1) | WO2018005867A2 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102554448B1 (ko) * | 2016-06-29 | 2023-07-11 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 알파-시누클레인 응집의 구조-기반 펩타이드 저해제 |
| EP4149505A1 (en) | 2020-05-15 | 2023-03-22 | Vib Vzw | Means and methods for the treatment of pathological aggregation |
| EP3943947A1 (en) * | 2020-07-22 | 2022-01-26 | Universitat Autònoma de Barcelona | Inhibitors of alpha-synuclein aggregation and uses thereof |
| CN116457466A (zh) * | 2020-09-23 | 2023-07-18 | 西洛斯治疗有限公司 | 用于抑制α-突触核蛋白聚集的组合物和方法 |
| EP4071165A1 (en) | 2021-04-05 | 2022-10-12 | Consejo Superior de Investigaciones Científicas (CSIC) | A new non-aggregative splicing isoform of human tau is decreased in alzheimer s disease |
| CN114645052B (zh) * | 2021-07-01 | 2023-05-26 | 中国医学科学院医学生物学研究所 | 一种全脑过表达核易位人源α-突触核蛋白转基因鼠的高效构建方法 |
| EP4186918A1 (en) | 2021-11-30 | 2023-05-31 | Université de Rennes | Inhibitory peptides for the diagnostic and/or treatment of tauopathies |
| KR20230131017A (ko) * | 2022-03-04 | 2023-09-12 | 삼성전자주식회사 | 가속기에 대해 온-디멘드 체크포인트를 수행하는 전자 장치 및 그 동작 방법 |
| DE102022105391A1 (de) | 2022-03-08 | 2023-09-14 | Forschungszentrum Jülich GmbH | Entwicklung eines α-Synuclein Amyloidtracers |
| WO2023181070A1 (en) * | 2022-03-23 | 2023-09-28 | Council Of Scientific & Industrial Research | PEPTIDE TO TREAT α-SYNUCLEIN AMYLOID BASED DISORDERS |
| US11932594B1 (en) | 2023-10-31 | 2024-03-19 | King Faisal University | 8-((2-hydroxy-5-methylphenyl)diazenyl)naphthalene-1,3-disulfonic acid as an antioxidant compound |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002004482A1 (en) * | 2000-07-07 | 2002-01-17 | Panacea Pharmaceuticals, Inc. | Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| GB0216972D0 (en) * | 2002-07-22 | 2002-08-28 | Univ Lancaster | Peptides and peptide derivaties for the treatment of &-synuclein-related diseases |
| JPWO2004113535A1 (ja) * | 2003-06-22 | 2007-09-20 | 早出 広司 | 凝集抑制作用を有するシヌクレイン変異体 |
| EA200900064A1 (ru) * | 2006-07-03 | 2009-06-30 | Запалойд Лимитед | Ингибирование агрегации альфа-синуклеина |
| CA2657847A1 (en) * | 2006-08-04 | 2008-02-07 | Lonza Biologics Plc | Method for predicting protein aggregation and designing aggregation inhibitors |
| PT2099826E (pt) * | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
| GB0716885D0 (en) * | 2007-08-30 | 2007-10-10 | United Arab Emirates Universit | Diagnostic agent |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| US8754034B2 (en) * | 2009-02-06 | 2014-06-17 | The Regents Of The University Of California | Structure-based design of peptide inhibitors of amyloid fibrillation |
| WO2010103515A2 (en) * | 2009-03-09 | 2010-09-16 | Ramot At Tel Aviv University Ltd. | Compositions and methods for prevention and treatment of neurodegenerative diseases |
| JP6126009B2 (ja) * | 2010-11-17 | 2017-05-10 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | α−シヌクレイン発現の調節 |
| CN102504016B (zh) * | 2011-12-08 | 2014-05-28 | 清华大学 | 淀粉样蛋白纤维性寡聚体构象型抗原表位多肽及其应用 |
| CA2962400A1 (en) * | 2014-09-25 | 2016-03-31 | Oxeia Biopharmaceuticals, Inc. | Methods of treating traumatic brain injury |
| KR102554448B1 (ko) * | 2016-06-29 | 2023-07-11 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 알파-시누클레인 응집의 구조-기반 펩타이드 저해제 |
-
2017
- 2017-06-29 KR KR1020197002859A patent/KR102554448B1/ko active IP Right Grant
- 2017-06-29 EP EP17821295.7A patent/EP3478311A4/en active Pending
- 2017-06-29 CN CN202310477400.0A patent/CN116650617A/zh active Pending
- 2017-06-29 JP JP2018568852A patent/JP6968839B2/ja active Active
- 2017-06-29 CA CA3029676A patent/CA3029676A1/en active Pending
- 2017-06-29 CN CN201780051045.3A patent/CN109641028A/zh active Pending
- 2017-06-29 US US16/311,593 patent/US10815271B2/en active Active
- 2017-06-29 WO PCT/US2017/040106 patent/WO2018005867A2/en active Application Filing
- 2017-06-29 KR KR1020237023052A patent/KR20230109776A/ko not_active Application Discontinuation
- 2017-06-29 IL IL263913A patent/IL263913B1/en unknown
- 2017-06-29 RU RU2019102202A patent/RU2766711C2/ru active
- 2017-06-29 MX MX2019000047A patent/MX2019000047A/es unknown
-
2019
- 2019-01-07 MX MX2023009652A patent/MX2023009652A/es unknown
-
2020
- 2020-05-26 US US16/883,515 patent/US11390646B2/en active Active
-
2021
- 2021-10-27 JP JP2021175108A patent/JP7337132B2/ja active Active
-
2022
- 2022-06-24 US US17/848,736 patent/US20230069905A1/en active Pending
-
2023
- 2023-08-22 JP JP2023134385A patent/JP2023162287A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019102202A (ru) | 2020-07-29 |
| US20210002329A1 (en) | 2021-01-07 |
| JP2022025103A (ja) | 2022-02-09 |
| US20230069905A1 (en) | 2023-03-09 |
| KR102554448B1 (ko) | 2023-07-11 |
| CN109641028A (zh) | 2019-04-16 |
| JP6968839B2 (ja) | 2021-11-17 |
| EP3478311A2 (en) | 2019-05-08 |
| US20190241613A1 (en) | 2019-08-08 |
| IL263913B1 (en) | 2024-09-01 |
| US11390646B2 (en) | 2022-07-19 |
| MX2023009652A (es) | 2023-08-24 |
| RU2766711C2 (ru) | 2022-03-15 |
| JP2019524685A (ja) | 2019-09-05 |
| MX2019000047A (es) | 2019-07-04 |
| WO2018005867A2 (en) | 2018-01-04 |
| CA3029676A1 (en) | 2018-01-04 |
| JP2023162287A (ja) | 2023-11-08 |
| KR20230109776A (ko) | 2023-07-20 |
| JP7337132B2 (ja) | 2023-09-01 |
| EP3478311A4 (en) | 2021-01-06 |
| US10815271B2 (en) | 2020-10-27 |
| KR20190034214A (ko) | 2019-04-01 |
| WO2018005867A3 (en) | 2018-02-01 |
| CN116650617A (zh) | 2023-08-29 |
| IL263913A (en) | 2019-01-31 |